Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity
The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Islamic University Sunan Kalijaga
2023-02-01
|
| Series: | Biology, Medicine & Natural Product Chemistry |
| Online Access: | https://sciencebiology.org/index.php/BIOMEDICH/article/view/299 |
| _version_ | 1797744203282776064 |
|---|---|
| author | Emuesiri Goodies Moke Endurance Efe Ahama Pere-Ebi Yabrade Toloyai Mamerhi Taniyohwo Enaohwo Ekuerhare Basil Emuesiri Kohworho Umukoro Anthony Taghogho Eduviere Ikuesirioghene Udumebraye Choice Udufowe |
| author_facet | Emuesiri Goodies Moke Endurance Efe Ahama Pere-Ebi Yabrade Toloyai Mamerhi Taniyohwo Enaohwo Ekuerhare Basil Emuesiri Kohworho Umukoro Anthony Taghogho Eduviere Ikuesirioghene Udumebraye Choice Udufowe |
| author_sort | Emuesiri Goodies Moke |
| collection | DOAJ |
| description | The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated comorbidities since loss of the ACE2 receptor due to SARS-Cov-2 infection can lead to increased blood pressure. The effects and clinical characteristics associated with the use of beta-blockers, angiotensin receptor blockers (ARB), and calcium-channel blockers (CCB) shows not to affect the outcome of covid-19, except in angiotensin converting enzyme inhibitor (ACEI) which may have negative outcomes on covid-19 infected patients. Many comorbidities have shown to be associated with the severity of the viral infection. |
| first_indexed | 2024-03-12T15:06:22Z |
| format | Article |
| id | doaj.art-6e5c02f32cc849dba74fc2baf6f7590c |
| institution | Directory Open Access Journal |
| issn | 2089-6514 2540-9328 |
| language | English |
| last_indexed | 2024-03-12T15:06:22Z |
| publishDate | 2023-02-01 |
| publisher | State Islamic University Sunan Kalijaga |
| record_format | Article |
| series | Biology, Medicine & Natural Product Chemistry |
| spelling | doaj.art-6e5c02f32cc849dba74fc2baf6f7590c2023-08-12T13:09:00ZengState Islamic University Sunan KalijagaBiology, Medicine & Natural Product Chemistry2089-65142540-93282023-02-0112119119610.14421/biomedich.2023.121.191-196169Antihypertensive Drugs Therapy in Hypertension and Covid-19 ComorbidityEmuesiri Goodies Moke0Endurance Efe Ahama1Pere-Ebi Yabrade Toloyai2Mamerhi Taniyohwo Enaohwo3Ekuerhare Basil4Emuesiri Kohworho Umukoro5Anthony Taghogho Eduviere6Ikuesirioghene Udumebraye7Choice Udufowe8Delta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaDelta State University, AbrakaThe novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. Many comorbidities have shown to be associated with the severity of the viral infection with hypertension being one of the highest rated comorbidities since loss of the ACE2 receptor due to SARS-Cov-2 infection can lead to increased blood pressure. The effects and clinical characteristics associated with the use of beta-blockers, angiotensin receptor blockers (ARB), and calcium-channel blockers (CCB) shows not to affect the outcome of covid-19, except in angiotensin converting enzyme inhibitor (ACEI) which may have negative outcomes on covid-19 infected patients. Many comorbidities have shown to be associated with the severity of the viral infection.https://sciencebiology.org/index.php/BIOMEDICH/article/view/299 |
| spellingShingle | Emuesiri Goodies Moke Endurance Efe Ahama Pere-Ebi Yabrade Toloyai Mamerhi Taniyohwo Enaohwo Ekuerhare Basil Emuesiri Kohworho Umukoro Anthony Taghogho Eduviere Ikuesirioghene Udumebraye Choice Udufowe Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity Biology, Medicine & Natural Product Chemistry |
| title | Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity |
| title_full | Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity |
| title_fullStr | Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity |
| title_full_unstemmed | Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity |
| title_short | Antihypertensive Drugs Therapy in Hypertension and Covid-19 Comorbidity |
| title_sort | antihypertensive drugs therapy in hypertension and covid 19 comorbidity |
| url | https://sciencebiology.org/index.php/BIOMEDICH/article/view/299 |
| work_keys_str_mv | AT emuesirigoodiesmoke antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT enduranceefeahama antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT pereebiyabradetoloyai antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT mamerhitaniyohwoenaohwo antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT ekuerharebasil antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT emuesirikohworhoumukoro antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT anthonytaghoghoeduviere antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT ikuesiriogheneudumebraye antihypertensivedrugstherapyinhypertensionandcovid19comorbidity AT choiceudufowe antihypertensivedrugstherapyinhypertensionandcovid19comorbidity |